Good News on Listing | Frost & Sullivan Congratulates Yifang Biotechnology (Shanghai) Co., Ltd. on Successfully Listing on the Sci-tech Innovation Board

Yifang Biotechnology (Shanghai) Co., Ltd. (hereinafter referred to as 'Yifang Biotech') successfully went public on July 25, 2022, issuing a total of 115 million shares at an issue price of 18.12 yuan per share.

Yifang Biotech is an innovative drug R&D enterprise based in China with a global perspective, focusing on major disease areas such as oncology and metabolic diseases. Yifang Biotech selects promising drug targets based on in-depth research and understanding of the mechanisms of disease action. Starting from the binding conformation of compounds and targets, they design drugs that achieve precise treatment of diseases while ensuring excellent human safety. Leveraging outstanding and rich drug development capabilities and experience, the company has independently developed a series of innovative targeted drugs protected by patents, covering tumors such as non-small cell lung cancer, breast cancer, and colorectal cancer, as well as metabolic diseases such as hyperuricemia and gout. In the future, Yifang Biotech continues to adhere to the concept of solving unmet clinical needs, dedicated to developing innovative drugs with independent intellectual property rights, Chinese innovation, and targeting the global market. It is committed to providing patients with safer, more effective, and affordable treatment options through persistent efforts.

Frost & Sullivan has long been monitoring the global and Chinese biopharmaceutical industries, publishing a large number of research reports that are widely cited in the prospectuses of leading science and technology innovation board listed companies in the industry, helping clients accelerate their growth.

With the continuous progress of molecular genetics research, studies on key gene mutations in non-small cell lung cancer have become increasingly in-depth. These genetic variations present on oncogenes can encode signaling proteins that regulate cell proliferation and survival, leading to the development of various specific molecular targeted drugs. In 2020, the market size of targeted drugs for non-small cell lung cancer in China reached 291 billion yuan. With the reform of medical insurance and the continuous emergence of domestic innovative drugs, the accessibility of targeted drugs for non-small cell lung cancer has been continuously improving. The market for targeted drugs for non-small cell lung cancer in China has huge market demand and development potential, with the expectation to reach 1042 billion yuan by 2025 and further to 1840 billion yuan by 2030.

The Chinese EGFR inhibitor market grew from 2.2 billion yuan in 2016 to 10.8 billion yuan in 2020, with a compound annual growth rate of 48.9%. Due to the continuous improvement of EGFR mutation detection methods, patients can detect EGFR mutations earlier and more accurately and receive EGFR inhibitor treatment. From 2020 to 2025, it is estimated that the market size of EGFR inhibitor drugs in China will increase by 27.7% annually to reach 368 billion yuan by 2025, and it is also expected that the market will reach 602 billion yuan by 2030 at a compound annual growth rate of 10.4% during the period from 2025 to 2030.

Currently, the global SERD targeted drug market size is mainly driven by the sales of fulvestrant, which decreased from $800 million in 2016 to $600 million in 2020, with a compound annual growth rate of -7.8% during this period. Considering the gradual launch of oral SERD targeted drugs in the future and their potential to exhibit better clinical efficacy and patient compliance, it is expected that the global SERD targeted drug market size will expand in the future. From 2020 to 2025, the global SERD targeted drug market size is expected to have an average annual compound growth rate of about 32.4%, reaching $24 billion by 2025. In the following five years, the average annual compound growth rate will decline but still maintain high-speed growth, with an expected average annual compound growth rate of 22.4% to reach $66 billion by 2030.

The market scale of SERD targeted drugs in China has grown rapidly, increasing from 100 million yuan in 2016 to 700 million yuan in 2020, with a compound annual growth rate of 60.6% during this period. It is expected that the market scale of SERD targeted drugs in China will continue to expand in the future, with an average annual compound growth rate of 29.8% from 2020 to 2025, reaching a market size of 240 billion yuan by 2025. From 2025 to 2030, the average annual compound growth rate is predicted to be 28.9%, and the market scale of SERD targeted drugs in China will reach 860 billion yuan by 2030.